Table 2.
The status of ABCC11 SNP538 and IC50 for MTA in 13 adenocarcinoma cell lines
| SNP538 | IC50 for MTA (nM) | 95% CI | |
|---|---|---|---|
| NCI‐H23 | G/G | 72.16 | 45.08–115.5 |
| SK‐LC‐10 | G/G | 5.648 | 4.175–7.639 |
| VMRC‐LCF | G/G | 88.38 | 36.94–211.4 |
| SK‐LC‐1 | G/G | 49.48 | 36.51–67.06 |
| VMRC‐LCD | G/A | 21.39 | 14.78–30.96 |
| ACC‐LC‐314 | G/A | 75.88 | 49.16–117.1 |
| ACC‐LC‐MS | A/A | 31.01 | 19.39–49.60 |
| ACC‐LC‐176 | A/A | 1.102 | 0.8365–1.453 |
| NCU‐LC‐201 | A/A | 4.394 | 3.552–5.436 |
| ACC‐LC‐94 | A/A | 21.19 | 16.87–26.63 |
| PC‐14 | A/A | 14.74 | 11.14–19.51 |
| RERF‐LC‐MT | A/A | 48.94 | 33.91–70.63 |
| PC‐9 | A/A | 14.01 | 12.51–15.69 |
MTA, pemetrexed.